Previous 10 | Next 10 |
Theratechnologies Inc. (THTX) Q1 2022 Earnings Conference Call April 12, 2022 8:30 a.m. ET Company Participants Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais - SVP & Chief Medical Officer John Mullaly - IR, LifeSci Advisors Conference Call Particip...
The following slide deck was published by Theratechnologies Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Theratechnologies Inc. 2022 Q1 - Results - Earnings Call Presentation
Theratechnologies press release (NASDAQ:THTX): Q1 Net Loss of $9.03M Revenue of $18.56M (+20.3% Y/Y) misses by $3M. 2022 Revenue Guidance: The company affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022 vs consensus of $81.82M, or growth of ...
- Q1 2022 consolidated sales grew 20%, supported by 35% growth in EGRIFTA SV ® sales - TH1902 Phase 1/Part A enrollment at 300 mg/m 2 dose nearing completion, potentially enabling recruitment of larger Phase 1/Part B expansion (basket trial) in the...
Two Additional Preclinical Proof-of-concept Posters in Ovarian and Metastatic Lung Cancer Models Also Presented at the Meeting MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: TH...
MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its first quarter...
MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that three p...
Theratechnologies Inc. (THTX) Q4 2021 Earnings Conference Call February 24 2022 8:30 AM ET Company Participants John Mullaly - IR, LifeSci Advisors Paul Levesque - President and Chief Executive Officer Philippe Dubuc - SVP and Chief Financial Officer Christian Marsolais - SVP and Chief Medica...
Theratechnologies press release (NASDAQ:THTX): Q4 GAAP EPS of -$0.34 misses by $0.26. Revenue of $18.75M misses by $1.73M. For further details see: Theratechnologies GAAP EPS of -$0.34 misses by $0.26, revenue of $18.75M misses by $1.73M
- FY2021 consolidated sales grew 5.7% supported by strong EGRIFTA SV ® sales - Second half fiscal 2021 revenues grew 10% over 2020, while total new enrollments grew 24% as commercial execution strategy firmly carries momentum into 2022 - Lead onc...
News, Short Squeeze, Breakout and More Instantly...
Theratechnologies Inc. Company Name:
THTX Stock Symbol:
NYSE Market:
Theratechnologies Inc. Website:
Q2 revenue of $22 million represents +25% growth year-over-year Positive net income of $1 million realized with Adjusted EBITDA 1 of $5.5 million Fiscal 2024 revenue guidance confirmed between $87 and $90 million and an Adjusted EBITDA in the range of $13 to $15 mi...
MONTREAL, June 26, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will re...